Gao Rongyin, Zhang Ximei, Zou Kun, Meng Duo, Lv Jinpeng
Department of Pharmacy, Department of Dermatology, The first people's Hospital of Changzhou, The third Affiliated Hospital of Soochow University, Changzhou, China.
School of Pharmacy, Changzhou University, Changzhou, China.
Front Pharmacol. 2023 Feb 6;14:1081030. doi: 10.3389/fphar.2023.1081030. eCollection 2023.
Cutaneous pigmentation was recently shown to be an event regulated by clock proteins. Cryptochrome (CRY) is a key protein composing the feedback loop of circadian clock, however, the function of CRY in melanocytes remains unclear. Here, we found that KL001, a synthetic small molecule modulator of CRY1, inhibited melanin synthesis, as well as reduced melanocyte dendrite elongation and melanosome transport. In addition, the dominant role of CRY1 in KL001-induced anti-melanogenesis was revealed by small interfering RNA transfection. Cellular tyrosinase activity and expression level of melanogenic proteins, including tyrosinase, TRP-1, TRP-2, and transport proteins like Rab27a, Cdc42 and Myosin Va induced by α-MSH were remarkably reversed after KL001 treatment. Mechanistically, CRY1 activation inhibited melanogenesis through CREB-dependent downregulation of MITF and CREB phosphorylation was mediated by classical cAMP/PKA pathway. In addition, the other CRY1 activator, KL044 also suppressed cAMP/PKA/CREB pathway and inhibited melanogenesis. Finally, anti-melanogenic efficacy of KL001 was confirmed by determination of melanin contents in UVB-tanning model of brown guinea pigs, which indicated that targeting CRY1 activity, topical application of small molecule activator, can be utilized therapeutically to manage human pigmentary disorders.
皮肤色素沉着最近被证明是一个受生物钟蛋白调节的过程。隐花色素(CRY)是构成昼夜节律生物钟反馈回路的关键蛋白,然而,CRY在黑素细胞中的功能仍不清楚。在此,我们发现CRY1的合成小分子调节剂KL001可抑制黑色素合成,并减少黑素细胞树突伸长和黑素小体转运。此外,通过小干扰RNA转染揭示了CRY1在KL001诱导的抗黑色素生成中的主导作用。KL001处理后,α-MSH诱导的细胞酪氨酸酶活性以及包括酪氨酸酶、TRP-1、TRP-2等黑色素生成蛋白和Rab27a、Cdc42和肌球蛋白Va等转运蛋白的表达水平均显著逆转。机制上,CRY1激活通过依赖CREB的MITF下调抑制黑色素生成,且CREB磷酸化由经典的cAMP/PKA途径介导。此外,另一种CRY1激活剂KL044也抑制cAMP/PKA/CREB途径并抑制黑色素生成。最后,通过测定棕色豚鼠UVB晒黑模型中的黑色素含量,证实了KL001的抗黑色素生成功效,这表明靶向CRY1活性,局部应用小分子激活剂可用于治疗人类色素沉着紊乱。